Skip to content
MARKETS / NYSE / IQV
NYSE · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP

Iqvia Holdings Inc. IQV

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$16.3B
▲ 5.9% YoY
$1.4B
▼ 0.9% YoY
$2.1B
▼ 3.0% YoY
In brief

What this company does

IQVIA Holdings Inc. provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. It has approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence. Its data holdings include more than 1.2 billion non-identified patient records spanning sales, prescription, promotional, social media, medical claims, electronic medical record and genomics data, contained within approximately 68 petabytes of proprietary data sourced from approximately 150,000 data suppliers. It delivers information and insights on approximately 90% of the world's pharmaceuticals, as measured by 2024 sales. It has three reportable segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Its Technology & Analytics Solutions offerings include cloud-based applications and SaaS solutions supporting commercial and clinical processes such as customer relationship management, performance management, real-world evidence generation, compliance and safety reporting, and multi-channel marketing. Its Research & Development Solutions offerings enable the conduct and coordination of multi-site clinical trials across Phase I through IV. Its Contract Sales & Medical Solutions offerings include partnering with biopharmaceutical companies and other life sciences providers to deploy stakeholder engagement solutions, including contract sales and market access professionals, focused on product sales from initial market entry through patent expiry.

Written from the business description in IQVIA HOLDINGS INC.'s annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth
USD 16.3B
Revenue, FY2025 · full 15-year series below
Revenue $B Net income $B
FY2025 · Revenue 16.3 · Net income 1.4
8B16B20112013201520172019202120232025
Compound annual growth
+4.2%
+7.5%
+11.0%
+7.6%
+37.3%
+13.4%
+11.1%
+40.5%
+2.1%
+22.7%
+9.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +7.5% a year over five years — but profit grew faster: net income at +37.3%, earnings per share at +40.5%.

The share count fell from 0.19B to 0.17B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 13.4% · Net 8.3%
5%10%20112013201520172019202120232025
ROE
FY2025 · ROE 21.6%
10%20%20112013201520172019202120232025

Each USD of equity produced 22 cents of profit this year.

Cash & shareholders
USD 1.2B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 2.1
0.8B1.6B20112013201520172019202120232025
Net buybacks $B Dividends $B
FY2025 · Dividends — · Net buybacks 1.2
1.0B2.0B-0.2B-0.4B20112013201520172019202120232025

USD 1.2B in buybacks — 91% of the year's profit went back to shareholders.

Total assetsUSD 29.9B
EquityUSD 6.5B
CashUSD 2.0B
Gross debtUSD 15.7B
Net debtUSD 13.7B
Current ratio0.75×

Net debt stands at 211% of equity.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B16.315.415.014.413.911.411.110.49.76.85.75.55.14.94.3
Operating income $B2.22.22.01.81.40.70.80.70.70.60.60.60.50.40.3
EBITDA $B3.33.33.12.92.72.02.01.91.70.90.80.70.60.50.4
Income tax $B0.30.30.10.30.20.10.10.1−1.00.30.20.10.10.10.0
Net income $B1.41.41.41.11.00.30.20.31.30.10.40.40.20.20.2
Free cash flow $B2.12.11.51.62.31.30.80.80.60.70.40.30.30.30.1
EPS, diluted $7.847.497.295.724.951.430.961.245.740.473.082.721.771.512.05
Dividend / sh $···············
Payout %·············320119
ROE %21.622.6·18.116.04.63.03.515.41.8·····
Shares out B0.170.180.180.190.190.190.190.20·0.250.120.120.130.120.12

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 22 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2011

Share this section

Download image